Vericel (VCEL) Q2 2026 earnings review
Top-Line Strength Triggers Upgraded Guidance and $200M Buyback
Vericel delivered an exceptional Q2 2026, driving 22% total revenue growth and raising its full-year outlook. The core MACI franchise grew 23%, validating the recent sales force expansion and MACI Arthro adoption. Most notably, the company has hit a structural cash flow inflection point, generating $14.3 million in Free Cash Flow (up from near-zero a year ago). Flush with $227 million in cash and zero debt, management demonstrated conviction in the trajectory by authorizing a $200 million share repurchase program. However, investors should monitor profitability—despite record sales, Adjusted EBITDA margin compressed slightly YoY from 21% to 19% due to elevated operating expenses.
🐂 Bull Case
MACI revenue grew 23% YoY to $65.5M, maintaining a trailing four-quarter growth rate of 23%. Biopsies and implants reached record Q2 levels, proving the expanded sales force and Arthro delivery system are accelerating adoption.
With $227 million in cash, no debt, and robust free cash flow generation ($14.3M in Q2), the newly authorized $200 million buyback program provides a powerful floor for the stock and signals strong management confidence.
🐻 Bear Case
While revenue grew 22%, Gross Margin dipped to 73% (from 74% a year ago) and Adjusted EBITDA margin fell to 19% (from 21%). The costs of supporting an expanded commercial footprint are eating into incremental profitability.
Burn Care revenue of $12.0M grew 22% YoY, but growth is decelerating compared to the blistering 90% YoY surge seen in 26Q1. The segment relies heavily on unpredictable Epicel cases.
⚖️ Verdict: 🟢
Bullish. The combination of sustained 20%+ top-line growth, a raised full-year guide, and a massive $200M buyback authorization drastically outweighs the slight, expected margin compression from sales force investments.
Key Themes
MACI Arthro & Sales Expansion Fueling Growth
The MACI franchise is accelerating. Q2 net revenue hit $65.5M (+23% YoY), notching its fifth consecutive quarter of 20%+ growth. The strategic expansion of the sales force and the rollout of the less-invasive MACI Arthro instrument set are successfully driving double-digit growth in both biopsies and implants, effectively deepening penetration into smaller cartilage defects.
Free Cash Flow Inflection
Vericel has transitioned from a capital-intensive buildout phase to a cash-printing machine. Q2 Free Cash Flow was $14.3 million, accelerating massively from just $0.08 million in the prior year quarter. First half FCF hit $29.4 million, confirming that the new Burlington manufacturing facility is now supporting scalable, cash-generative growth.
NexoBrid Breaking Out with Macro Support
NexoBrid delivered a record quarter, growing 36% sequentially and 33% YoY to $1.5 million. The broader Burn Care segment is heavily supported by government/macro funding, evidenced by the recently announced $197M BARDA contract, which acts as a powerful non-dilutive catalyst for NexoBrid procurement and blast-trauma indication development.
Operating Leverage Reversing Temporarily
A clear red flag in an otherwise stellar quarter: Adjusted EBITDA margin decelerated to 19% from 21% a year ago. Total operating expenses spiked 15% to $56.0M, driven by headcount additions and MACI sales force marketing. Management is sacrificing near-term margin for market share. If procedure volumes slow, this higher fixed-cost base will punish profitability.
Burn Care Revenue Ceiling
Burn Care revenue plateaued sequentially at $12.0 million (identical to 26Q1). While still up 22% YoY, the heavy reliance on Epicel ($10.4M) leaves the franchise vulnerable to patient case cancellations—a volatility factor management explicitly warned about in prior periods.
Gross Margin Compression
Gross margin compressed slightly to 73% in 26Q2, down from 74% in 25Q2. While management reaffirmed a full-year target of approximately 75%, achieving this requires a massive margin step-up in the second half of the year, introducing execution risk.
Other KPIs
Reversing. Swung to a positive $2.2M ($0.04 EPS) compared to a net loss of $0.6M in the prior year. This proves the top-line growth is finally outrunning the depreciation burden of the new manufacturing facility.
Accelerating. Up from $161.4M at year-end 2025. With zero debt, this pristine balance sheet fully funds both the $200 million share repurchase program and ongoing clinical trials without risk of dilution.
Guidance
Accelerating. Guidance raised from $326-$336M. The new midpoint ($335M) implies a ~21% growth rate over FY25's $276M, indicating management sees no slowdown in H2 demand.
Accelerating. Raised from prior guidance of $282-$288M. The robust H1 performance (record biopsies and implants) derisks the back half of the year.
Accelerating. Raised from $44-$48M. Assumes continued Epicel stability and expected H2 deliveries to BARDA under the NexoBrid procurement contract.
Accelerating. Reaffirmed. Since H1 Adjusted EBITDA margin tracking is considerably lower (19% in Q2), this guidance implies a massive profitability step-up in Q3 and Q4, driven by expected heavy volume leverage.
Key Questions
Buyback Cadence
With the authorization of a $200 million share repurchase program, what is the anticipated timeline for deployment, and will purchases be programmatic or opportunistic?
H2 Margin Ramp
Q2 Adjusted EBITDA margin was 19%, yet full-year guidance remains at 27%. Beyond standard seasonal volume leverage in Q4, are there specific cost-saving levers being pulled in H2 to bridge this gap?
UK Expansion Costs
With the MACI marketing authorization application submitted to the U.K. MHRA, what level of commercial SG&A investment is required in the next 12-18 months to prepare for the targeted 2027 launch?